武田藥品更新了其2024財年的管理指導和報告及核心預測。這些調整主要受產品動能和運營費用節約的推動，同時也反映了修訂後的全年匯率假設。根據最新的預測，核心收入預計將小幅增長，而核心每股收益預計與之前持平或略微下降。此外，自由現金流的預期被上調至5500億至6500億日元。查看更多詳情，請參考《2024財年財務預測修訂公告（IFRS）》。

以上內容來自Benzinga Earnings專欄，原文如下：

FY2024 OutlookUpdating Full Year Management Guidance and Reported and Core Forecasts

Takeda has upgraded its FY2024 Management Guidance, primarily driven by product momentum and OPEX savings. In addition, and also reflecting revised foreign exchange assumptions for the year, Takeda has raised its FY2024 reported and Core forecasts from the previous forecast. For more details, see release: Notice of the Revised Forecast of Consolidated Financials for FY2024 (IFRS)

FY2024 Management Guidance Core Change at CER (Non-IFRS)
	FY2024 PREVIOUS MANAGEMENT GUIDANCE (October 2024)	FY2024 REVISED MANAGEMENT GUIDANCE (January 2025)
Core Revenue	Flat to slightly increasing	Low-single-digit % increase
Core Operating Profit	Mid-single-digit % decline	Low-single-digit % increase
Core EPS (Yen)	Approx 10% decline	Flat to slightly declining

FY2024 Reported and Core Forecasts
(Billion yen, except percentages and per share amounts)
	FY2024PREVIOUS FORECAST (October 2024)	FY2024 REVISED FORECAST (January 2025)
Revenue	4,480.0	4,590.0
Core Revenue (Non-IFRS)	4,480.0	4,590.0
Operating Profit	265.0	344.0
Core Operating Profit (Non-IFRS)	1,050.0	1,150.0
Net Profit	68.0	118.0
EPS (Yen)	43	75
Core EPS (Yen) (Non-IFRS)	456	507
Adjusted Free Cash Flow (Non-IFRS)	400.0-500.0	550.0-650.0
Annual Dividend per Share (Yen)	196	196